Estamos realizando la búsqueda. Por favor, espere...
1582
37
170
29108
4409
2600
347
389
Abstract: There is substantial evidence suggesting that individual variability in antipsychotic treatment response could be genetically determined. Variations in several serotonin transporter (5-HTT) gene polymorphisms have been associated with antipsychotic response among chronic patients with schizophrenia, although their implication in early response among first-episode patients remains unclear. Two polymorphisms in the 5-HTT gene (a 44 bp insertion/deletion in the promoter region and the functional polymorphism rs25531) were genotyped in a sample of 147 drug-naïve patients experiencing a first episode of a non-affective psychosis. Early (6 weeks) response to antipsychotic treatment with haloperidol, olanzapine or risperidone was assessed with the Brief Psychiatric Rating Scale, the Scale for the Assessment of Positive Symptoms, and the Scale for the Assessment of Negative Symptoms. No clear association was found between the rs25531 variant and treatment response. However, significant associations were observed between 5-HTT-LPR variants and early negative symptom response among first-episode patients with psychosis. Our results suggest a minor contribution to antipsychotic drug response of genetic alterations in the 5-HTT gene.
Fuente: Psychiatry Research, 2010, 175(3), 189-194
Editorial: Elsevier
Fecha de publicación: 28/02/2010
Nº de páginas: 6
Tipo de publicación: Artículo de Revista
DOI: 10.1016/j.psychres.2008.12.011
ISSN: 0165-1781,1872-7123
Url de la publicación: https://doi.org/10.1016/j.psychres.2008.12.011
Leer publicación
JAVIER VAZQUEZ BOURGON
ARRANZ, MARÍA JESÚS
IGNACIO MATA PASTOR
JOSE MARIA PELAYO TERAN
ROCIO PEREZ IGLESIAS
MEDINA-GONZÁLEZ, LAURA
JOSE LUIS VAZQUEZ BARQUERO
BENEDICTO CRESPO FACORRO
EUGENIO CARRASCO MARÍN
Volver